Back to Results
First PageMeta Content
Piperazines / Pathogenic bacteria / Pneumonia / Gram-positive bacteria / Levofloxacin / Ofloxacin / Quinolone / Mycoplasma pneumoniae / Klebsiella pneumoniae / Bacteria / Medicine / Microbiology


Document Date: 2009-03-31 17:13:57

Open Document

File Size: 25,47 KB

Share Result on Facebook

City

Fishers Lane Rockville / Raritan / /

Company

M.P.H. / /

Currency

USD / /

IndustryTerm

supplemental new drug applications / drug product / supplemental applications / drug products / /

MedicalCondition

arrhythmia / pneumonia / hypokalemia / significant bradycardia / severe community-acquired pneumonia / torsades de pointes / disease / community-aquired pneumonia / community-acquired pneumonia / Communityacquired pneumonia / severe disease / /

Organization

Food and Drug Administration / Division of Drug Marketing / Advertising / and Communications / Special Pathogen and Immunologic Drug Products Office / FDA / Center for Drug Evaluation and Research / Division of Special Pathogen / /

Person

Mark J. Goldberger / Mary Ellen Zamstein / Jeffrey Fritsch / /

/

Position

Director / physician / Principal Regulatory Scientist / Regulatory Affairs / General / Regulatory Project Manager / /

Product

levofloxacin / penicillin / LEVAQUIN / /

ProvinceOrState

New Jersey / Maryland / /

Technology

drug development / /

URL

www.fda.gov/cder/pediatric / /

SocialTag